Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-12-02
2000-06-06
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544283, 544284, 544287, 544288, 544293, A61K 31505, C07D23972, C07D40100, C07D40300
Patent
active
060719214
ABSTRACT:
The invention relates to quinazoline derivatives of the formula: ##STR1## [wherein: Y.sup.1 represents --O--, --S--, --CH.sub.2 --, --SO--, --SO.sub.2 --, --NR.sup.5 CO--, --CONR.sup.6 --, --SO.sub.2 NR.sup.7 --, --NR.sup.8 SO.sub.2 -- or --NR.sup.9 -- (wherein R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 each independently represents hydrogen, alkyl or alkoxyalkyl);
REFERENCES:
patent: 3266990 (1966-08-01), Lutz et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 5373011 (1994-12-01), Haley
patent: 5411963 (1995-05-01), Dreikom et al.
patent: 5457105 (1995-10-01), Barker
patent: 5475001 (1995-12-01), Barker et al.
patent: 5571815 (1996-11-01), Schaper et al.
patent: 5580870 (1996-12-01), Barker et al.
patent: 5962458 (1999-10-01), Lohmann et al.
Senger et al., Vascular permeability factor (VPF, VEGF) in tumor biology, Cancer and Metastasis Reviews, 1993, pp. 303-324.
Kolch et al., Regulation of the expression of the VEGF/VPS and its receptors: role in tumor angiogenesis, Breast Cancer Research and Treatment, 1995, pp. 139-155.
Folkman, Angiogenesis in cancer, vascular, rheumatoid and other disease, Nature Medicine, 1995, pp. 27-31.
Fan et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, Trends Pharmacol. Sci., 1995, 57-66.
Connolly et al., Human Vascular Permeability Factor--Isolation from U937 Cells, J. Biol. Chem. 1989, pp. 20017-20024.
Cullinan-Bove et al., Vascular Endothelial Growth Factor/Vascular Permeability Factor Expression in the Rat Uterus: Rapid Stimulation by Estrogen Correlates with Estrogen-Induced Increases in Uterine Cappillary Permeability and Growth, Endocrinology, 1993, pp. 829-837.
Kim et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, 1993, pp. 841-844.
Jakeman et al., Developmental Expression of Binding Sites and Messenger Ribonucleic Acid for Vascular Endothelial Growth Factor Suggests a Role for This Protein in Vasculogenesis and Angiogenesis, Endocrinology, 1993, pp. 848-859.
Rewcastle et al., "Tyrosine Kinase Inhibitors. 5. Synthesis and Structure-Activity Relationships for 4-[(Phenylmethyl)amino]-and 4-(Phenylamino)quinazolines as Potent Adenosine 5'-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor," J.Med.Chem. 1995, vol. 38, pp. 3482-3487.
Burke, Jr., "Protein-tyrosine kinase inhibitors," Drugs of the Future 1992, vol. 17(2), pp. 119-131.
Spence, "Inhibitors of Tyrosine Kinase Activity as Anticancer Therapeutics: Recent Developments," Current Opinion in Therapeutic Patents, Jan. 1993, Patent Update, Anticancers, etc., pp. 3-9, Current Drugs Ltd ISSN 0962-2594.
Lin et al., Chem.Abs., vol. 96:122728w, 1982, p. 695.
Spada, et al., Small molecule inhibitors of tyrosine Kinase activity, Exp.Opin.Ther.Patents (1995), 5(8):805-817, Patent Update, Oncologic, Endocrine & Metabolic, Ashley Publications Ltd ISSN 1354-3776.
Bridges, "The current status of tyrosine kinase inhibitors: do the diarylamine inhibitors of the EGF receptor represent a new beginning?," Exp.Opin.Ther.Patents (1995), 5(12): 1245-1257, Editorial, Oncologic, Endocrine & Metabolic, 1995 Ashley Publications Ltd ISSN 1354-3776.
Traxler, et al., "Recent advances in protein tyrosine kinase inhibitors," Drugs of the Future 1995, vol. 20(12, pp. 1261-1274.
Li, et al., Chem.Abs., vol. 92:76455u, 1980, p. 674-675.
Iyer, et al., "Studies in Potential Amoebicides: Part III-Synthesis of .sub.4 -Substituted Amino-8-Hydroxy) Quinazolines & .sub.3 -Substituted 8-Hydroxy(&8-Methoxy)-.sub.4 -Quinazolones," J.Sci.Industr.Res., vol. 15C, Jan. 1956, pp. 1-7.
Kobayashi, Derwent Abstract 82-87077, vol. 6, No. 244, Dec. 1982, JP 57-144266, Sep. 1982, "4-Anilinoquinazoline Derivative, its Preparation and Analgesic and Antiphlogistic Agent Containing Said Derivative as Active Component".
Sankyo and Ube, Derwent Abstract 81-28290, JP 56-20577, Feb. 1981, "4-(N-alkyl:anilino) quinazoline derivs . . . having analgesic and antiinflammatory actions".
Kyorin, Derwent Abstract 84-53835, JP 59-13765, Jan. 1984, "2-(4-Quinazolinyl)amino benzoic acid derivs . . . having analgesic and antiinflammatory activities".
Fry et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," Science, vol. 265, Aug. 19, 1994, pp. 1093-1095.
Buchdunger, et al., "4,5-Dianilinophthalimide: A protein-throsine kinase inhibitor with selectivity of or the epidermal growth factor receptor signal transduction pathway and potent in vivo antitumor activity," Prac.Natl.Acad.Sci., USA, vol. 91, pp. 2334-2338, Mar. 1994, Applied Biological Sciences.
Trinks, et al., "Dianilinophthalimides: Potent and Selective, ATP-Competitive Inhibitors of the EGF-Receptor Protein Tyrosine Kinase," J.Med. Chem. 1994, vol. 37, pp. 1015-1027.
Maguire, et al., "A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Subsituted Quinoline Derivatives," J.Med.Chem. 1994, vol. 37, pp. 2129-2137.
Dolle, et al., "5,7-Dimethoxy-3-(4-pyridinyl)quinoline Is a Potent and Selective Inhibitor of Human Vascular .beta.-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase," J.Med.Chem. 1994, vol. 37, pp. 2627-2629.
Bridges, et al., "Enantioselective Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase by 4-(.alpha.-Phenethylamino)quinazolines," Bioorganic & Medicinal Chemistry, vol. 3, No. 12, pp. 1651-1656, 1995.
Ward, et al., "Epidermal Growth Factor Receptor Tyrosine Kinase--Investigation of Catalytic Mechanism, Structure-Based Searching and Discovery of a Potent Inhibitor," Biochem.Pharmacology, vol. 48, No. 4, pp. 659-666 (1994).
Hennequin Laurent Francois Andre
Lohmann Jean-Jacques Marcel
Thomas Andrew Peter
Kifle Bruck
Shah Mukund J.
Zeneca Limited
Zeneca Pharma S.A.
LandOfFree
Chemical compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemical compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemical compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2213821